{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'However, if a constellation of signs and/or symptoms cannot be medically characterized as a', 'single diagnosis or syndrome at the time of reporting, each individual event should be', 'recorded on the AEs eCRF page. If a diagnosis is subsequently established, all previously', 'reported AEs based on signs and symptoms should be nullified and replaced by 1 AE report', 'based on the single diagnosis, with a starting date that corresponds to the starting date of the', 'first symptom of the eventual diagnosis.', 'Each AE is to be evaluated for date and time to onset, duration, severity, seriousness, and', 'potential relatedness to the study treatment and/or study procedure (i.e., any procedure', 'required by the study protocol). The action taken and the outcome must also be recorded in', 'the AE page of the eCRF.', '7.4.5.1', 'Patient-Reported Outcome Data', 'Adverse event reports will not be derived from PRO data. However, if any subject responses', 'suggestive of a possible AE are identified during study site review of the PRO', 'questionnaires, study site staff will alert the Investigator, who will determine if the criteria', \"for an AE have been met and will document the outcome of this assessment in the subject's\", 'medical record per study site practice. If the event meets the criteria for an AE, it will be', 'reported on the AEs eCRF.', 'Information contained within the subject diary (see Section 5.5) will not be considered PRO', 'data.', '7.4.5.2', 'Reporting of Serious Adverse Events', 'All SAEs that occur at or after Visit 1 (OLE Baseline/Week 24), regardless of the', \"Investigator's assessment on causality, must be recorded on the relevant pages of the eCRF\", 'and reported to R-Pharm International according to protocol requirements.', 'Investigators must report the SAE within 24 hours of first becoming aware of the event. All', 'SAEs must be reported via the EDC system by completing the relevant eCRF pages in', 'English. In the event that the EDC system is not functioning, SAEs must be reported within', '24 hours of first becoming aware of the event using the back-up paper SAE report form', '(instructions provided in the Investigator binders). Once the EDC system is operating', 'normally again, Investigators must enter the SAE in the eCRF pages. All SAEs should be', 'followed up as detailed in Section 7.4.5.5, and the timelines and procedure for follow-up', \"reports are the same as those for the initial report. R-Pharm International's designee is\", 'responsible for managing the safety database.', \"R-Pharm International will be alerted of all SAEs occurring during a subject's follow-up\", \"regardless of the Investigator's assessment of causality. SAEs occurring after a subject has\", 'Amendment 2: 06 March 2019', '110', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'received the last dose of study treatment will be collected and reported to R-Pharm', \"International's designee through the end of the Safety Follow-Up Period (i.e., for a period of\", \"22 weeks after the last dose of study treatment), regardless of the Investigator's opinion of\", 'causality. The Investigator must also inform participating subjects of the need to inform the', 'Investigator of any SAE that occurs within this period. Any SAE with a start date after the', 'Follow-Up Period is not required to be reported unless the Investigator thinks that an event', 'may be related to either the study treatment, study treatment administration, or a protocol', 'procedure.', '7.4.5.3', 'Reporting of Serious Adverse Events to Regulatory Authorities and', 'Investigators', \"R-Pharm International's designee will be responsible for reporting all suspected unexpected\", 'serious adverse reactions (SUSARs) and any other applicable SAEs to regulatory authorities,', 'ethics committees, and Investigators, in accordance with national regulations in the countries', 'where the study is conducted. Relative to the first awareness of the event by/or further', \"provision to R-Pharm International's designee, SUSARs will be submitted within 7 days for\", 'fatal and life-threatening events and 15 days for other SUSARs, unless otherwise required by', \"national regulations. R-Pharm International's designee will also prepare an expedited report\", 'for other safety issues where these might materially alter the current benefit-risk assessment', 'of OKZ or that would be sufficient to consider changes in the study treatment administration', 'or in the overall conduct of the study. The study site will also forward a copy of all', 'expedited reports to the relevant Independent Ethics Committee (IEC) or Institutional', 'Review Board (IRB) in accordance with national regulations.', '7.4.5.4', 'Follow-up of Adverse Events', 'Any AEs that occur at or after Visit 1 (OLE Baseline/Week 24) until the end of the Safety', 'Follow-Up Period (i.e., 22 weeks after the last dose of study treatment) will be followed up', 'to resolution. Resolution means that the subject has returned to a baseline state of health, the', 'Investigator does not expect any further improvement or worsening of the AE, or the subject is lost to', 'follow-up. The Investigator should follow each SAE until the event is resolved or returned to', 'the baseline, the event is assessed as stable by the Investigator, the subject is lost to', 'follow-up, or the subject withdraws consent. For AEs with a causal relationship to the study', \"treatment, R-Pharm International or its designee must concur with the Investigator's\", 'assessment.', \"For SAEs, nonserious AESIs, and pregnancies, R-Pharm International's designee may\", 'follow-up by telephone, fax, electronic mail, and/or a monitoring visit to obtain additional', 'case details and outcome information (e.g., from hospital discharge summaries, consultant', 'Amendment 2: 06 March 2019', '111', 'Confidential']\n\n###\n\n", "completion": "END"}